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Edible vaccine technology represents an alternative to fermentation based vaccine production system. 
Transgenic plants are used for the production of plant derived specific vaccines with native 
immunogenic properties stimulating both humoral and mucosal immune responses. Keeping in view 
the practical need of new technology for production and delivery of inexpensive vaccines, especially in 
developing world, plant derived edible vaccines is the best option in hand to combat infectious 
diseases. Plant derived vaccine is easy to administer, cost effective, readily acceptable, have increased 
safety, stability, versatility and efficacy. Several plant derived vaccines are under research, some are 
under clinical trials for commercial use. Like most biotechnology products, the IP situation for edible 
vaccines is complex as IP rights influence every stage of vaccine development.  
 





Transgenic plants are the plants in which foreign genes 
of desired characters have to be inserted. Transgenic 
plant have been found to have many advantages like, 
development of high yielding varieties of crop plants and 
disease resistant, and are plants with improved tolerance 
to biotic and abiotic stress (Ahmad et al., 2008; 2010a; b; 
2011; Ahmad and Umar, 2011; Ahmad and Prasad, 
2012a; b; Sarwat et al., 2012). Apart from the above, 
transgenic plants have been employed for the production 
of vaccines for the treatment of various infectious 
diseases (Kant et al., 2011; Vianna et al., 2011; Yoshida 
et al., 2011; Sharma and Sood, 2011; Twyman et al., 
2012). Infectious diseases are major cause of mortality 
and morbidity worldwide (Goldblatt and Ramsay, 2003) 
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and one-third of the deaths are caused by the infectious 
agents. Vaccine is an immuno-biological substance, used 
for specific protection against both infectious and non-
infectious diseases (reviewed by Ahmad et al., 2012; 
Twyman et al., 2012). Vaccine is responsible for the stimu-
lation of protective antibody and other immune mecha-
nisms. The vaccines can be made from live or killed 
inactivated organisms, extracted cellular fractions, toxoid 
or combination of these. Recent preparations are sub-unit 
vaccines and recombinant vaccines. The main limitation 
with vaccines is their dependence on cold chain system, 
which is used to store and transport the vaccine under 
strict controlled conditions (Park, 2005). Other limitations 
are risk of adverse reactions such as reactions inherent 
to inoculation, reactions due to faulty techniques etc 
(Goldblatt and Ramsay, 2003). Thus, for the implemen-
tation of a successful global vaccination strategy, a well 
designed subunit oral vaccine system should satisfy the 
following criteria (Chargelegue et al., 2005; Levine et al., 
2006; Nochi et al., 2007): (a) Produce sufficient quantities 
of desired antigen; (b) preserve the expressed antigen for 
a long time at room temperature; (c) induce protective 
immunity; (d) be protected from enzymatic digestion in 
the gastrointestinal tract.  
Therefore, in the 1990s, an International campaign was 
initiated to immunize all the world's children against six 
devastating diseases. The target was to reach 80% of 
infants and reduce the annual death toll from these 
infections by roughly three million. Still, 20% of infants 
are un-immunized by six vaccines against polio, measles, 
diphtheria, pertusis, tetanus and tuberculosis. In many 
developing countries, millions of children still die from 
infectious diseases due to immunizations being non-
existent, unreliable or too costly (Ramsay et al., 1999). 
None will be entirely safe until every child has routine 
access to vaccines. Hence, there is an urgent need to 
search for vaccines which are easy to administer, easy to 
store, cost effective, easy to transport and possess 
readily acceptable delivery system. Hence, there is a lot 
of scope in developing plant derived vaccine (Streatfield 
et al., 2001; Ahmad et al., 2012). Now the question arises 
what is plant derived vaccine? Advances in transgenic 
research have made use of crop plants to serve as 
bioreactor for the production of recombinant molecules 
(Raskin et al., 2002; Kant et al., 2011; Vianna et al., 
2011; Yoshida et al., 2011; Sharma and Sood, 2011). 
This means that transgenic plants are used to express 
antigen proteins induced by plant transgenic vectors and 
to produce certain special vaccines with high anti-disease 
ability (reviewed by Mei et al., 2006; Malabadi et al., 
2012) (Figure 1). Plant derived vaccines significantly 
increase availability of vaccines in places where mainte-
nance of cold chain system is difficult (Webster et al., 
2002; Kant et al., 2011; Vianna et al., 2011; Yoshida et 
al., 2011; Sharma and Sood, 2011; Twyman et al., 2012). 
Important examples on the development of plant bio-





The immunogenicity and safety of plant derived vaccines 
was declared in phase I clinical studies (Tacket, 2009). 
During the last decade, different types of efficient plant-
based expression systems have been studied and more 
than 100 different types of recombinant proteins including 
plant-derived vaccine antigens have been successfully 
expressed in different types of plant tissues (Tiwari et al., 
2009; Rybicki, 2010; reviewed by Ahmad et al., 2012). 
Positive effects of edible vaccines include decrease in 
potential hazards such as toxic compounds, responses to 
allergy and risk of attenuated strains reverting to pathogenic 
strains associated with established production technologies 




TRANSGENIC PLANTS FOR THE PRODUCTION OF 
PLANT DERIVED VACCINES 
 
Through recombinant DNA technology, different level of 
antigen expression for each independent line has been 
observed
 
in plants (Karg and Kallio, 2009; Shih and 
Doran, 2009; Wilken and Nikolov, 2012). In 1990 first 
edible vaccine, surface protein A from Streptococcus 
mutans was expressed in tobacco (Curtis and Cardineray, 
1990). Plant derived vaccine in the form of seed or fruit 
can be easily stored and transported from one place to 
another without the worry of its degradation or damage. A 
large amount of plant derived vaccine can be easily 
produced by cultivation in fields with relatively few inputs. 
Autoimmune disorders like Type I diabetes, multiple 
sclerosis, rheumatoid arthritis etc., can also be suppressed 
by using plant derived vaccines (Prakash, 1996).  
Plants are selected which expresses highest level of 
antigen and least number of adverse effects. Till date 
various types of antigens are successfully expressed in 
different plants (Mason and Arntzen, 1995; reviewed by 
Ahmad et al., 2012). With the development of plant 
genetic engineering, the expression system for transgenic 
plants are no longer limited to model plants, but extended 
to some orally or high protein content plants. Various 
plant plateforms have been demonstrated for production 
of recombinant proteins in plants, including leafy crops, 
cereals and legume seeds, oil seeds, fruits, vegetables, 
higher plant tissue and cell cultures, hydroponic systems, 
algae and halobios (reviewed by Mei et al., 2006). Co-
expression of adjuvant along with antigen has also been 
done in the same plant (Lal et al., 2007). The use of rice 
storage protein gene promoters to express transgenes in 
rice grain is well documented (Nicholson et al., 2005).  
Furtado et al. (2008) compared use of storage protein 
gene promoter and non-storage gene promoter with 
regard to spatial and temporal control of expression from 
barely, wheat and rice. Storage protein promoter from 
barley and wheat directed the expression in endosperm 
but not in embryo; expression was leaky, as it was 
observed  in  seed maternal tissues, leaf and root tissues;  






Figure 1. Strategy for the production of candidate 




Table 1. Representative plant-based vaccines: under clinical development or in market. 
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whereas, rice promoters directed the endosperm-specific 
expression in transgenic rice (Furtado et al., 2008). 
Alfalfa (Medicago sativa) is considered as a good 
bioreactor for production of recombinant proteins as it 
contains high levels of protein content and low levels of 
secondary metabolites (Dus Santos et al., 2002). Cereal 
crops can be the most suitable candidate and can be 
used to enhance the antigen concentration and help to 
reduce oral dose as they have ample amount of soluble 
protein in endosperm (Ahmad et al., 2012). Potato, 
tomato and carrot have been successfully reported to 
express vaccine candidates (Walmsley and Arntzen, 
2000). Antigen genes encoding HBsAg, HIVgag and 
Rabies Capsid Proteins have been successfully trans-
formed to tomato (Sala et al., 2003). High levels of 
recombinant protein expression were observed in 
proplastids of cultured carrot cells (Daniell et al., 2005). 
Oral delivery of the therapeutic proteins via edible carrot 
preserved the structural integrity of their target proteins 
as no cooking is needed (Muller et al., 2003). Other 
vegetable crops like lettuce (Lactuca sativa), celery 
cabbage (Brassica rapa var. pekinensis), cauliflower 
(Brassica oleracea var. botrytis) are under study for the 
production of vaccines. The only problem in these 
vegetables is low expression levels (Koprowski, 2005; 
Tacket and Mason, 1999). The earliest fruit used for the 
plant transgenic programme is banana (Musa acuminate) 
(Mason et al., 2002).  
According to Trivedi and Nath (2004) papaya (Carica 
papaya) is another ideal plant species for vaccine 
production. Apart from fruit, vegetable and cereal crops 
scientists have used algae to produce metabolites and 
heterologous proteins for pharmaceuticals applications 
(Mayfield and Franklin, 2005). The species under study 
are: Chlamydomonas reinhardii (Sun et al., 2003), 
Phaeodactylum tricornutum (Zaslavskaia et al., 2000), 
Amphidinium carterae, Symbiodinium microadriaticum 
(ten Lohuis and Miller, 1998) and Cylindrotheca fusiformis 
(Fischer et al., 1999). Exciting progress has been made 
with the chloroplast based production of two particularly 
important classes of pharmaceuticals, vaccines and anti-
bodies (Bock and Warzecha, 2010; Scotti et al., 2012). 
Extraordinarily high expression levels and the prospects 
of developing edible pharmaceuticals make transgenic 
chloroplasts a promising platform for the production of 
next-generation vaccines and antimicrobials (Waheed et 
al., 2012). During the past few years, several vaccine 
candidates have been produced successfully via plastid 
transformation, which emphasizes that transplastomic 
plants, as a second generation expression system, have 
great potential to fill gaps in conventional production 
platforms. A salient feature of plastids is that they combine 
characteristics of prokaryotic and eukaryotic expression 
systems, which is exemplified by the production of virus 
like particles and of bacterial antigens (reviewed by Bock 
and Warzecha, 2010). Successful expression of antigens 
in plants was carried out for Escherichia coli, heat labile 
enterotoxin B subunit (LT-B) in tobacco and potato (Hirst 
and Holmgren, 1987), Rabies virus G protein in tomato 
(Mc Garvery et al., 1995), Hepatitis B virus surface 
antigen in tobacco and potato (Thanavala et al., 1995), 
Norwalk virus capsid protein in tobacco and potato 
(Mason et al., 1996) and cholera toxin B subunit (CT-B) 
in potato (Arakawa, 1997).  
Antigen expressed in plant or plant products can be 
administered orally or by intramuscular or by intravenous 
injection. Homogenized leaves, fruits or vegetables are 
used  through oral route. Purified antigen containing plant 




tissue can be delivered in a capsule or powder (pill) form. 
Capsule may be suitable because capsule coating can be 
modified in such a way that coating material dissolves in 
particular area of stomach, and vaccine can be released 
in a specific area of the body. Purified component can 
also be used by intramuscular and intravenous admini-
stration. Oral administration of plant derived vaccine 
induces both mucosal and systemic immunity. When 
antigen is administered orally, it induces more mucosal 
response than intramuscular or intravenous injections. 
So, more importance has been given to those antigens, 
which induce mucosal immune response to produce 
secretory Ig A at mucosal surfaces. Mucosal immunity is 
very effective in diarrhoeal diseases caused by rotavirus, 
Norwalk virus, Vibrio cholerae, entero toxigenic E. coli 
(ETEC) and also in respiratory diseases such as 
pneumonia.   
Second generation plant derived vaccines are known 
as multi component vaccines, provides protection against 
several pathogens. Both Enterotoxigenic Escherichia coli 
(ETEC) heat-labile enterotoxin (LT-B) and the capsid 
protein of Norwalk virus were successfully expressed in 
plants and induced immune response against both E. coli 
and Norwalk virus in mice (Huang et al., 2001).  
 
 
ADVANTAGES OF EDIBLE VACCINES OVER 
INJECTED VACCINES 
 
Edible vaccines have many advantages over the injected 
vaccines like: 
 
1. Edible vaccines are cost effective, have low risk of 
contamination and no cost for transportation. 
Pharmaceutical companies spend million dollars for the 
production of vaccines and to preserve vaccines. 
Transgenic plants does not need cold chain storages. 
2. Pharmaceutical companies need the hitech machines 
for the production of vaccines. In the case of edible 
vaccines production we need soil rich land instead of 
machines. 
3. Long distance transportation is not required in the case 
of edible vaccines. 
4. The cost of materials needed for field grown plants is 
lower compared to cell culture grown in bioreactors (Xu et 
al., 2011). 
5. Edible vaccines have a low cost for medical equipment 
as well, because needles and syringes are not needed 
for delivery (Streatfield, 2006; Xu et al., 2011). 
6. Medical professionals are not needed for oral delivery 
(Streatfield, 2006). 
7. Transgenic plants have low contamination risks as 
compared to injected vaccines 
8. Needles and syringes are responsible for spreading of 
second hand diseases (Nochi et al., 2007). 
9. Oral delivery has efficiency to provoke a mucosal 





responses (Streatfield, 2006). 
Edible vaccines have multi-component ability that is 
possible due to the crossing of 2 plant lines (Lal et al., 
2007). These vaccines with multi-component abilities are 
known as second generation edible vaccines as they 
allow for several antigens to approach M cells (microfold 
cells) simultaneously (Lal et al., 2007). The multi-
component edible vaccines can prevent multiple diseases 
for example ETEC, chlorea and ratovirus (Lal et al., 
2007). Injected vaccines do not have this property, so 
there are less effective than edible vaccines (Ramessar 





Over-coat and epi-coat technology is used to produce 
chimeric viruses. Over-coat technology provides 
expression of entire protein, whereas epi-coat technology 
permits the plant to produce only the foreign proteins 
(http://www.geocities.com/plantvaccines/transgenicplants
.html). Plant viruses redesigned to carry the desired 
genes and used to infect differently in different parts of 
the plant. Alfalfa mosaic virus, CaMV (Cauliflower mosaic 
virus), CpMV (Cow pea mosaic virus), TMV (Tobacco 
mosaic virus), Tomato bushy stunt virus and Potato virus 
are redesigned to express fragments of antigens on their 
surface. There are reports that they produce plant based 
chimeric virus such as foot and mouth disease virus; mint 
enteritis virus. Fragment of gp41 surface protein of HIV 
virus put into CpMV could evoke a strong neutralizing 




APPROACHES TO PRODUCE PLANT DERIVED 
VACCINES 
 
Plants serve as an important source to produce cost-
effective vaccine derivatives. Plant based production of 
vaccine candidates can help to reduce the economic 
burden on the developing countries and can be made 
easily available to every individual. Various models to 





Enterotoxigenic Escherichia coli (ETEC) 
 
Enterotoxigenic Escherichia coli strains are a major 
cause of enteric diseases in live stock and humans. 
ETEC is attached to specific receptors on the surface of 
enterocytes in the intestinal lumen by fimbriae. ETEC 
produces a heat-stable enterotoxin (ST) which consists of 
five B subunits and one A subunit. B subunit binds to 





villi and crypts of the small intestine. Insertion of the B 
subunit into the host cell membrane forms a hydrophilic 
transmembrane channel through which the toxic A 
subunit can pass into the cytoplasm (Roy et al., 2010). 
Raw transgenic potato expressing LT-B were fed to 11 
volunteers, out of which 10(91%) developed neutralizing 
antibodies and 6(55%) of individuals also showed 
mucosal response (Tacket et al., 1998). Different reports 
are there on synthetic heat-labile enterotoxin (LT-B) gene 
and their expression in plants such as potato, banana, 
tobacco and tomato; and all were tested in mice (Mason 
et al., 1998). Expression of E. coli fimbrial subunit protein 
in transgenic plants can be used to vaccinate against 
these diseases. Joensuu et al. (2006) evaluated 
transgenic plants to produce Fae G protein and adhesion 
of F4 fimbriae. Oakes et al. (2007) reported the edible 
transgenic soyabean plant producing E. coli fimbrial 
subunit proteins. Tacket (2009) discussed early human 
studies of oral transgenic plant-derived vaccines against 
enterotoxigenic Escherichia coli. Genetic combination of 
gene coding for an LTB:ST protein in tobacco by 
Agrobacterium mediated transformation displays 
antigenic determinants from both LTB and ST. Presence 
of mucosal and systemic humoral responses in mice 
when dosed orally with transgenic tobacco leaves also 
confirmed that plant-derived LTB:ST can lead to 
immunogenicity development via oral route (Rosales-





Cholera is due to contaminated food or water which 
triggers an acute intestinal infection by V. cholera (López-
Gigosos et al., 2011). Enterotoxin such as cholera toxin 
(CT) was expressed in tobacco plant (Arakawa et al., 
1998). Nochi et al. (2007), showed oral immunization with 
transgenic rice encoding the cholera toxin B subunit 
(CTB) which stimulates secretory Ig A, shows resistant to 
gastrointestinal digestion. Karaman et al. (2012) 
introduced synthetic gene encoding for CT-B by the 
control of a γ-zein promoter in maize seeds. CT-B levels 
were checked via ganglioside dependent ELISA. Anti-
CTB IgG and anti-CTB IgA were found in the sera and 
fecal samples of the orally immunized mice protected 





Anthrax is a disease most commonly occur by inoculation 
of B. anthracis through the skin of infected animals, their 
products and inhalation of spores in dust or wool fibers. 
Virulence factors is a toxin complex, which consists of 
three proteins. The protective antigen (PA) binds the 
complex receptors on the macrophage surface. After 
proteolysis, oedema factor and lethal factor are released  




which after endocytosis, blocks the adenyl cyclase pathway 
within the cell. The main effect of this toxin complex is to 
increase vascular permeability, which leads to a shock. 
Protective antigen was expressed in transgenic tobacco 
chloroplasts by inserting the pag A gene into the chloroplast 
genome. Cytotoxicity measurements
 
in macrophage lysis 
assays showed that chloroplast-derived PA
 
was equal in 
potency to PA produced in B. anthracis.  Chloroplast-
derived protective antigen provides cleaner and safer 
anthrax plant-derived-vaccine at a lower production cost 
(Koya et al., 2005). Koya et al. (2005) published for the 
first time the PA expression in plants from stable nuclear-
transgenic tobacco. Aziz et al. (2002) also reported the 
expression of PA in leaves of stable nuclear-transgenic 
tomato plants. Expression of PA in tobacco or tomato 
was enhanced in combination with a second B. anthracis 
protein, lethal factor (LF), and showing cytolytic activity 
when applied to macrophage-like cell lines. Also, when 
tomato leaf material was injected into mice, antisera 
could be recovered with neutralizing activity to anthrax 





Periodontal diseases are caused by oral anaerobic 
bacterium Porphyromanas gingivalis. It is thought to be 
initiated by the binding of P. gingivalis fimbrial protein to 
saliva coated oral surfaces. Shin et al. (2009) has success-
fully transferred FIM A protein producing gene into potato 








Calci viruses are a major cause of food and water 
associated outbreaks of diarrhoea and vomiting, affecting 
individuals of all age groups. A capsid protein of Norwalk 
virus was expressed in transgenic tobacco and potato 
plants. Potato tubers expressing Norwalk virus antigen 
were fed to mice, it developed serum IgG specific for 
Norwalk virus (Mason et al., 1996). According to Tacket 
et al. (2000) volunteers fed with transgenic potato 
expressing Norwalk virus antigen showed seroconversion. 
 
 
Hepatitis B virus 
 
It is estimated that 3 to 6% of the world population has 
been infected with Hepatitis B virus (HBV) and there are 
300 to 400 million carriers in the world. India alone has 
over 40 million carriers. In the acute stage there are signs 
of inflammation in the portal triads: the infiltrate is mainly 
lymphocytic.   In the  liver  parenchyma, single cells show  




ballooning and form acidophilic (councilman) bodies as 
they die. In chronic hepatitis, damage extends out from 
the portal tracts, giving the piecemeal necrosis appearance. 
Some lobular inflammation is also seen. As the disease 
progresses fibrosis develops and eventually, cirrhosis. 
Hepatitis B virus replicates in the hepatocytes, reflected 
in the detection of viral DNA and HBs Ag in the nucleus 
and HBs Ag in the cytoplasm and at the hepatocyto-
membrane (Simmonds and Peutherer, 2003). Hepatitis B 
virus is carried in the blood and blood derived bodily 
fluids of infected persons and can be transferred through 
contact with a carrier’s blood caused by unsafe injections 
or transfusions, sexual contact and tattooing. Long term 
protection against Hepatitis B virus is possible with 
vaccine. HBs Ag was expressed in transgenic potato 
plant and tested in mice for production of antibodies 
(Richter et al., 2000).   
Pniewski et al. (2011) has shown the production of 
small surface antigen for HBV (S-HBsAg) in genetically 
modified glufosinate-resistant lettuce. They orally immu-
nised mice by using lyophilised form of plant material and 
showed the presence of secretory IgA (S-IgA) and total 
serum antibodies. Li et al. (2011) also demonstrated the 
transformation of HBsAg (hepatitis B surface antigen) 
gene in to tomato mediated by Agrobacterium tumifaciens. 
Lou (2007)
 
has experimentally expressed hepatitis B 
virus large surface antigen in transgenic tomato plant. 
Transgenic lettuce plant carrying recombinant hepatitis B 
virus antigen HBs Ag was demonstrated in Brazil 
(Marcondes and Hansen, 2008). Tacket (2009) has 
discussed early human studies of oral transgenic plant-
derived vaccines against hepatitis B virus. A phase I 
clinical trial with plant derived hepatitis B vaccine has 






Millions of people live in areas where measles are 
endemic and resources are scare. Measles are 
transmitted from person to person by respiratory droplets. 
Measles in an acute febrile illness, the onset is flu-like 
with high fever, cough and conjunctivitis, red spots with a 
bluish-white centre on the buccal mucosa called Koplik’s 
spots. Measles antigens expressed in plants have been 
shown to be antigenic and immunogenic both after 
invasive and oral vaccination (Marcondes and Hansen, 
2008). Crude Quillaja saponin extracts stimulates measles’ 
virus specific immune responses in mice, following oral 
immunization with plant based measles virus haema-
gglutinin protein (Pickering et al., 2006). 
Webster et al. (2002) confirmed that the transgenic 
tobacco plants-derived MV-H protein vaccine, which when, 
modified to MV-H DNA vaccine, to prime-boost vaccination 
strategy demonstrated the MV hemagglutinin protein 










JE virus is a single stranded positive sense RNA virus 
belonging to family flaviviridae transmitted through a 
zoonotic cycle between mosquitoes, pigs and water birds. 
It causes encephalitis all over the world especially in 
Eastern and South-eastern Asia. JE affects some primary 
organs like thalamus, corpus striatum, brainstem and 
spinal cord. With the absence of specific antiviral therapy, 
it is managed mainly by its symptom and by supportive 
therapies along with preventive measurements (Misra 
and Kalita, 2010). Transgenic rice expressing the envelope 
protein of Japanese encephalitis virus (JEV), under control 
of a dual cauliflower mosaic virus (CaMV 35s) promoter, 
was generated. JEV specific neutralizing antibody was 
detected in mice after immunization of mice with protein 
extracts from transgenic rice plant by intraperitoneal or 
oral immunization (Wang et al., 2009). Appaiahgari et al. 
(2009) showed the expression of Japanese encephalitis 
viral envelope protein (E) in transgenic tobacco can 
produce immunogenic response in mammalian system.  
 
 
Influenza virus H5N1 
 
Shoji et al. (2009) described the production of hema-
gglutinin from A/Indonesia/05/05 strain of H5N1 influenza 
virus by transient expression in plants. The results indicate 
that immunization of ferrets with plant-derived hema-
gglutinin elicited serum hemagglutinin-inhibiting antibodies 
and protected the ferrets against challenge infection with 
a homologous virus. Plant derived vaccine may be the 
solution in the rapid, large scale production of influenza 
vaccine in the face of pandemic. 
Kalthoff et al. (2010) showed the expression of full-
length recombinant hemagglutinin (rHA0) of H5N1 in 
Nicotiana benthamiana with optimize expression levels. 
Their results showed to provide an immunogenic protection 
protect chicken against lethal challenge infection with 
heterologous HPAIV H5N1 of 96% homology to rHA0 by 
plant-expressed hemagglutinin. Jul-Larsen et al. (2012) 
demonstrated recombinant influenza haemagglutinin 
antigen (HAC1) that was derived from the 2009 pandemic 
H1N1 virus and expressed in tobacco plants. They showed 
that the tobacco derived recombinant HAC1 antigen is a 
promising vaccine candidate recognized by both B- and T 
cells. 
Shoji et al. (2011) showed the advantages provided by 
the plant system for influenza vaccine antigen production 
is their independence from pathogenic viruses, and cost 
and time efficiency. They produced large-scale of 
recombinant hemagglutinin proteins from 
A/California/04/09 (H1N1) and A/Indonesia/05/05 (H5N1) 





tested their immunogenicity (serum hemagglutination 
inhibition and virus neutralizing antibodies), and safety in 
animal models. 
Madhun et al. (2011) produced influenza subunit antigen 
in transient plant expression systems as an alternative. A 
needle-free intranasal influenza vaccine is an attractive 
approach to be followed. Plant-derived influenza H5N1 
(A/Anhui/1/05) antigen, alone or formulated with bis-(3', 
5')-cyclic dimeric guanosine monophosphate (c-di-GMP) 
as adjuvant induces strong mucosal and systemic 
humoral immune responses. Search for safe and 
effective adjuvant to enhance H5N1 intranasal vaccine 
with extracts of mushroom mycelia was found to be good 





Before the commercial production of plant derived 
vaccines, there is urgent need to consider the following 
points; 
 
1. Searching for suitable plant which will give ideal 
antigen expression. 
2. Identification of proper dosage (whether plant parts, 
plant products, pill, intramuscular or intravenous injection 
of purified antigen) can produce proper dose. 
3. Verification of allergens in the plant and plant products. 
4. Study the impact of plant derived vaccines on the 
environment and human health. 
5. Genetically altered crops producing plant derived 
vaccine could get mixed with human food supply or 
animal feed, causing potential threat to public health. 
6. Cross pollination and their problems. 
7. Effects on insects and soil microbes. 
8. Regulation of plant derived vaccines in the form of 
food, drug or agricultural product. 
9.  Cultivation of plant derived vaccines and their delivery 
in capsule or pill form. 
 
 
Risks of plant derived vaccines 
 
Plant derived vaccines pose serious risks to the public if 
they are not handled with care. Safety of transgenic 
plants includes many aspects like ecology, agronomy and 
molecular biology which focus on food and environmental 
safety (Ahmad et al., 2012). Environmental issues and 
biodiversity concern are raised because of the transgenic 
seeds or plants that escape into the wild. Moreover, plant 
derived vaccines cannot be distinguished from non-plant 
derived vaccines of the same plant. Plant derived vaccine 
tomato plant looks like a traditional tomato. There is 
always a risk of mis-administration. 
Although, plant derived vaccine technology can save 
many lives in developing countries. At the same time, 
there   is   an  urgent need to address proper commercia- 




ization of plant derived vaccine technology and to prevent 
misuse of technology because it possesses great risk on 
environment and human health. Development of vaccine 
into a stable seed form or production in leaf is mostly 
favoured but its to spoilage to prevent loss/leaking out of 
antigen into environment is to be checked. The amount of 
plant which can be taken up as raw food is to be strictly 
monitored as over dose may cause toxic/allergic 
reactions. Most of the edible crops are destroyed by 
attack of insects and hence their effect on vaccine 
producing plant has to be evaluated. Even though plant 
derived vaccines have shown promising results but 
evaluation of their tolerance needs in-depth study 
(Ahmad et al., 2012). 
 
 
CONCLUSION AND FUTURE PERSPECTIVE 
 
Edible plant derived vaccine may lead to a future of safer 
and more effective immunization. They would overcome 
some of the difficulties associated with traditional 
vaccines like production, distribution and delivery and 
they can be incorporated in to the immunization plans. 
Edible vaccines have lot of advantages over injected 
vaccines like, well established cultivation, low cost of 
production, no need for “cold chain” delivery, rapid scale-
up, simple distribution by seeds, ease of genetic 
manipulation, oral delivery and low health risks from 
human pathogen and toxin contamination, etc. Significant 
progress has been achieved in employing plants as 
vaccine expression system, for example vegetables, 
fruits, cereal crops, etc. Tobacco, tomato, maize, rice are 
leading production plateforms for recombinant protein 
production. The basic advantage of using plants as 
vaccine production system is that plants being higher 
eukaryotes provide opportunities for unlimited production, 
the range and diversity of recombinant molecules namely 
peptides, polypeptides and complex multimeric proteins 
that cannot be made in microbial systems. Plant 
production system provides a wider flexibility in designing 
of new pharmaceutical proteins. Days are not too far 
when we eat delicious vegetables, fruits etc, to prevent 
ourselves from infectious diseases. Developing and 
under-developed countries will be benefited more by this 
edible vaccine production system because the methods 
in production are reasonably affordable and the vaccine 
products would be more openly accessible to the 
population. 
One of the most important bottlenecks in edible vaccine 
technology is yield improvement, as this factor has a 
major impact on economic feasibility. Different strategies 
in hand which can lead to improved production of edible 
vaccines include the development of novel promoters, 
improvement in protein stability by protein engineering 
approach, targeted expression of protein of interest and 
last but not least the improvement in downstream process-
sing.  The  potential concern of edible vaccine technology 




is differential glycosylation of proteins in in vitro systems 
or in non-native species. Strategies should be devised to 
humanize the plant glycosylation machinery by inhibiting 
glycosylation enzymes. The use of plastids as vaccine 
production platform is quite promising to prevent 
transgene escape through pollens or seed dispersal and 
it needs an extensive research to improve expression 
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